pharma · Multiple Myeloma · Ovarian Cancer · CASIF
CASI Pharmaceuticals
CASI Pharmaceuticals is a pharma organization headquartered in San Francisco, USA. It trades on NYSE under ticker CASIF. Primary therapeutic focus areas include Multiple Myeloma, Ovarian Cancer, Advanced Cancer, Recurren
601 Gateway Blvd, San Francisco, CA 94080, US HQ
44 Employees
Public company Type
CASIF · NYSE Ticker
Company details
- Status
- Public
- HQ
- 601 Gateway Blvd, San Francisco, CA 94080, US
- Employees
- 44
- Programs
- 22
- Drugs
- 11
- Patents
- 2
melphalan hydrochloride for injection
Approved · small molecule · Multiple Myeloma
melphalan hydrochloride for injection for Multiple Myeloma is a Approved program (small_molecule) at CASI Pharmaceuticals with 2 ClinicalTrials.gov record(s).
Internal code 2021PHD013-001
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- CASI Pharmaceuticals
- Phase
- Approved
- Modality
- small_molecule
- Indication
- Multiple Myeloma
- Status
- active
- Trials
- 2